NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free EW Stock Alerts $92.86 +0.55 (+0.60%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$91.95▼$93.0450-Day Range$72.55▼$93.8152-Week Range$60.57▼$95.27Volume2.90 million shsAverage Volume4.20 million shsMarket Capitalization$55.84 billionP/E Ratio40.37Dividend YieldN/APrice Target$88.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingHold2.47 Rating ScoreUpside/Downside5.2% Downside$88.00 Price TargetShort InterestHealthy1.43% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.86Based on 24 Articles This WeekInsider TradingSelling Shares$16.45 M Sold Last QuarterProj. Earnings Growth11.96%From $2.76 to $3.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.58 out of 5 starsMedical Sector96th out of 947 stocksSurgical Appliances & Supplies Industry4th out of 18 stocks 2.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 9 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $88.00, Edwards Lifesciences has a forecasted downside of 5.2% from its current price of $92.86.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.43% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 16.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.7 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Edwards Lifesciences this week, compared to 10 articles on an average week.Search InterestOnly 17 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat FollowsOnly 45 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,445,296.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.25% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 11.96% in the coming year, from $2.76 to $3.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 40.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 40.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 227.15.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 8.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesMarch 17, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $156,030.70 in StockMarch 14, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,319,645.00 in StockMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 12, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,320,192.00 in StockMarch 16, 2024 | finance.yahoo.comEW Apr 2024 100.000 callMarch 16, 2024 | finance.yahoo.comCAH Apr 2024 123.000 callMarch 15, 2024 | americanbankingnews.comDonald E. Bobo, Jr. Sells 14,500 Shares of Edwards Lifesciences Co. (NYSE:EW) StockMarch 15, 2024 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives Average Recommendation of "Hold" from AnalystsMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 14, 2024 | markets.businessinsider.comBuy Rating on Edwards Lifesciences Amid Expanding TAVR Market and Positive SMART Trial OutlookMarch 13, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Upgraded to Buy at StockNews.comMarch 12, 2024 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) VP Jean-Luc M. Lemercier Sells 14,400 SharesMarch 11, 2024 | businesswire.comLarge, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVRMarch 10, 2024 | finance.yahoo.comEW Aug 2024 97.500 callMarch 10, 2024 | americanbankingnews.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells $156,030.70 in StockMarch 9, 2024 | finance.yahoo.comTMO Mar 2024 572.500 callMarch 9, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Stock Rating Upgraded by Bank of AmericaMarch 7, 2024 | realmoney.thestreet.comBofA gets more bullish on Edwards Lifesciences, upgrades sharesMarch 7, 2024 | realmoney.thestreet.comEdwards Lifesciences upgraded to Buy at BofA after 'bullish' management meetingsMarch 7, 2024 | finance.yahoo.comEW Jun 2024 65.000 callMarch 7, 2024 | msn.comBofA upgrades Edwards to buy, says double-digit growth is backMarch 6, 2024 | wsj.comEdwards Lifesciences Corp.March 4, 2024 | markets.businessinsider.comBuy Rating on Edwards Lifesciences Amidst Strong TAVR Business and Promising TMTT ExpansionFebruary 29, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - EWFebruary 24, 2024 | msn.comEdwards Lifesciences (EW) Price Target Increased by 15.65% to 93.15February 23, 2024 | businesswire.comEdwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare ConferenceFebruary 22, 2024 | finance.yahoo.comIf You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth NowSee More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2024Today3/18/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$88.00 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside-5.2%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$2.30 Trailing P/E Ratio40.37 Forward P/E Ratio33.64 P/E Growth4.63Net Income$1.40 billion Net Margins23.35% Pretax Margin26.61% Return on Equity23.56% Return on Assets16.81% Debt Debt-to-Equity Ratio0.09 Current Ratio3.38 Quick Ratio2.40 Sales & Book Value Annual Sales$6.00 billion Price / Sales9.30 Cash Flow$2.75 per share Price / Cash Flow33.79 Book Value$11.08 per share Price / Book8.38Miscellaneous Outstanding Shares601,300,000Free Float593,543,000Market Cap$55.84 billion OptionableOptionable Beta1.05 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $1.04MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.09MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.1MMr. Jean-Luc Lemercier (Age 67)Corporate Vice President of Japan, Asia Pacific & Greater China Comp: $1.24MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.26MMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNDexComNASDAQ:DXCMView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 9,390 shares on 3/15/2024Ownership: 0.002%Donald E Bobo JrSold 14,500 sharesTotal: $1.32 M ($91.01/share)Cove Private Wealth LLCBought 12,769 shares on 3/12/2024Ownership: 0.002%Vanguard Group Inc.Bought 729,984 shares on 3/11/2024Ownership: 8.708%Jean-Luc M LemercierSold 14,400 sharesTotal: $1.32 M ($91.68/share)View All Insider TransactionsView All Institutional Transactions Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Friday, March 15, 2024 at 4:11 AM. Pros Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences reported a strong revenue growth of 13.3% compared to the same quarter last year, indicating a positive trend in the company's financial performance. The company's net margin of 23.35% showcases efficient cost management and profitability, which can be attractive to investors seeking stable returns. Analysts forecast a growth in earnings per share for the current fiscal year, indicating potential for increased profitability and shareholder value. Recent insider activity, with senior executives selling shares at higher prices, could signal confidence in the company's future prospects and stock performance. Positive ratings and price target upgrades from Wall Street analysts suggest a favorable outlook for Edwards Lifesciences Co., potentially leading to stock price appreciation. Cons Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: Despite revenue growth, the company's stock price may already reflect the positive performance, potentially limiting short-term gains for investors. High insider selling activity in the past three months could raise concerns about management's long-term confidence in the company's growth trajectory. Market volatility and regulatory changes in the healthcare sector could impact Edwards Lifesciences Co.'s operations and financial results, leading to uncertainty for investors. Competitive pressures in the medical research industry may pose challenges to Edwards Lifesciences Co.'s market share and profitability, affecting investor returns. Analysts' mixed ratings, including a sell rating from one analyst, indicate differing opinions on the company's future performance, potentially causing uncertainty among investors. EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 17 brokerages have issued twelve-month target prices for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they anticipate the company's stock price to reach $88.00 in the next year. This suggests that the stock has a possible downside of 5.2%. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 on January 1st, 2024. Since then, EW stock has increased by 21.8% and is now trading at $92.86. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a decline in short interest in February. As of February 29th, there was short interest totaling 8,440,000 shares, a decline of 16.4% from the February 14th total of 10,090,000 shares. Based on an average daily trading volume, of 4,380,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 1.4% of the company's shares are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings results on Tuesday, February, 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. The company's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.64 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), Fidelity Disruptive Medicine ETF (FMED), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS) and Goldman Sachs Future Health Care Equity ETF (GDOC). When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 0.620-0.660 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.71%), Vanguard Group Inc. (8.63%), Brown Advisory Inc. (3.00%), Wellington Management Group LLP (2.80%), Capital International Investors (1.49%) and Norges Bank (1.40%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.